Actelion to Acquire CoTherix, Inc
Actelion is going to acquire Cotherix for $425 million in another recent pharmaceutical deal.
PharmaLive: Actelion Announces Definitive Agreement to Acquire US-Based CoTherix, Inc.:
Again this deal is at a large premium; 72% over the closing price approx. a month ago. The main product from CoTherix is Ventavis (iloprost) an inhaled treatment of Pulmonary Arterial Hypertension (PAH).
This is another case where companies with a long-standing relationship eventually ends up in an acquisitions. Again the deal makes sense from a strategic point of view since both have a focus on PAH but I tend to think that again the price may have been too high.
Technorati Tags: Actelion, Cotherix, pharma M&A, pharmaceutical deals, iloprost, Ventivis
Related Posts:
Bookmark it with:
| 
del.icio.us
| 
Digg it
| 
Furl
| 
Simpy
| 
Spurl
| 
My Yahoo!
|
